Inflammatory bowel disease (IBD) is characterized by a chronically inflamed mucosa of the gastrointestinal tract, caused by an underlying immune imbalance and triggered by luminal substances, including bacteria. Mucus forms a gel layer covering the gastrointestinal tract, acting as a semi-permeable barrier between the lumen and the epithelium. Mucins, the building blocks of the mucus gel, determine the thickness and properties of mucus. In IBD in humans, alterations in both membrane-bound and secretory mucins have been described involving genetic mutations in mucin genes, changes in mucin mRNA and protein levels, degree of glycosylation, sulphation, and degradation of mucins. As mucins are strategically positioned between the vulnerable mucosa and the bacterial contents of the bowel, changes in mucin structure and/or quantity probably influence their protective functions and therefore constitute possible aetiological factors in the pathogenesis of IBD. This hypothesis, however, is difficult to prove in humans. Animal models for IBD permit detailed analysis of those aspects of mucins necessary for protection against disease. These models revealed pertinent data as for how changes in mucins, in particular in MUC2, imposed by immunological or microbial factors, may contribute to the development and/or perpetuation of chronic IBD, and shed some light on possible strategies to counteract disease.
The two forms of chronic human inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, are diseases primarily characterized by chronic inflammation of parts of the gastrointestinal tract. These are complex diseases caused by multiple environmental and genetic factors involving: (1) the immune system, (2) microbial factors, and (3) the intestinal epithelial barrier. Existence of an immune imbalance is one of the critical factors in the manifestation of IBD. Proof for this comes from various animal models with altered T-cell populations or cytokine deficiencies that spontaneously develop colitis, as reviewed elsewhere [1, 2] . Microbial factors are implicated in the initiation and/or perpetuation of disease. The development of colitis in many animal models can be prevented or attenuated if animals are maintained in a germ-free environment or are treated with oral antibiotics [3] [4] [5] . Considering that the epithelium and its associated mucus layer form a physical barrier between bacteria and cells of the immune system, it is more than probable that the epithelial barrier plays an important role in IBD. In support of this are several animal models in which a primary change in integrity of the epithelium leads to IBD-like syndromes. For instance, transgenic mice expressing a dominant-negative mutant of cadherin on their small intestinal enterocytes spontaneously develop IBD, caused by breaching of the epithelial barrier [6] . In another model, mice deficient in the multi-drug resistant protein (mdr1a), which is normally found in the intestinal epithelium, spontaneously develop colitis. These IBD-like symptoms resolved under antibiotic treatment, indicating that bacteria critically affect the epithelium [7] . Mice carrying a homozygous knockout mutation in the trefoil factor-3 gene prove very sensitive to developing colitis, whereas supplementation of these knockout mice with trefoil factor-3 reverted the disease [8] . Each of these examples illustrates that many proteins expressed in intestinal epithelial cells are, directly or indirectly, involved in the protective epithelial barrier against IBD.
Mucins, as the primary constituents of extracellular mucus and the cellular barrier, are intimately associated with each of the three aetiological factors of IBD. Mucins are important epithelial products of the intestine, essential for a proper epithelial barrier function, whereas both inflammatory mediators and bacterial factors are identified that influence their expression. Moreover, mucins are very important in the contact of many microorganisms with the intestinal mucosa. Therefore, a primary defect in mucins could breach the epithelial barrier or lead to altered mucosal-bacterial interactions. On the other hand, the changing effects of immunological or bacterial factors during initial or ongoing inflammation could influence the mucin production, could have further adverse effects on these processes, sustaining the chronic character of IBD. Mucin expression and structure was influenced by cytokines, bacteria, and bacterial components in in-vitro experiments on intestinal cell lines [9] [10] [11] [12] [13] , which has contributed considerably to the interest in mucins as possible aetiological factors in IBD.
MUC-type mucins in human intestine
Mucus forms a semi-permeable barrier between the intestinal lumen and the underlying epithelium, and is composed primarily of secretory gel-forming mucins like MUC2 [14] . Other mucins exist in the intestine, like MUC3 found in intestinal microvilli, that are membrane bound and form integral components of the apical side of the epithelial cells, but seem to be no part of the mucus layer.
Biochemically, mucins are usually very large, filamentous molecules (molecular weight up to several millions). Mucins have very large regions within their polypeptides, which comprise relatively short tandemly repeated peptide domains, which are highly O-glycosylated [14, 15] . The O-linked carbohydrates form up to 80% of the molecular weight of the mucins. These very numerous, yet relatively short (two to 20 monosaccharides), carbohydrate chains are very tightly packed along the polypeptide and are responsible for the overall filamentous structure of mucins. The addition of very large numbers of sulphate and sialic acid residues to the O-linked carbohydrates gives the mucins a highly negative surface charge.
Many of the known human mucin genes are presently assembled in the MUC gene family. The current nomenclature of the mucins is meanwhile challenged, as there appear to be large differences in primary sequence as well as function among the MUC-type mucins [16] . Functionally, MUC-type mucins can be subdivided into three classes: (1) secretory, gel-forming mucins, (2) membrane-bound mucins, and (3) small soluble mucins.
Secretory, gel-forming mucins
Secretory, gel-forming mucins are widely acknowledged as important players in the defence of the gastrointestinal epithelium, and are produced in specialized mucous cells of glandular tissues and goblet cells of gastrointestinal tract [14, [17] [18] [19] . These mucins are produced as disulphide-linked oligomers [20] , which proves essential for their ability to form viscoelastic mucus gels. There are four members to this group, MUC2, MUC5AC, MUC5B, and MUC6, and these are well characterized [21, 22] . In the healthy human colon, MUC2 is the predominant mucin produced by all goblet cells, and MUC5B is expressed in minor quantities in a subset of goblet cells at the bottom of the colonic crypts [18, 19, 23] . MUC5AC and MUC6 are normally confined to gastric epithelium [24] and are not expressed in the healthy intestines, but these MUCs appear in the colon in IBD [25, 26] .
Membrane-bound mucins
The membrane-bound mucins have been shown to be involved in epithelial cell signalling, adhesion, growth, and modulation of the immune system [17, [27] [28] [29] [30] [31] . Membrane-bound mucins are made in serous cells or epithelial cells, like enterocytes [15, 30] . Of the membrane-bound mucins, MUC1, MUC3A, MUC3B, MUC4 have been extensively studied, and their expression was also analysed in IBD [25, 32, 33] .
Small soluble mucins
So far, only one small soluble human mucin has been identified (MUC7), which is found in saliva [34] . As MUC7 was not studied in IBD, it will not be discussed further. Other genes have been assigned to the MUC family (MUC8, MUC11, MUC12, MUC13, and MUC16) [35] [36] [37] [38] . Although some of these are expressed in the intestine [36, 37] , their involvement in IBD has not yet been analysed.
Genetic deviations in human MUC3A are associated with IBD
It has long been known that IBD has a certain genetic predisposition, and therefore many investigators have sought to identify chromosomal loci in the human genome that predispose for IBD. Among the different susceptibility loci identified for IBD is 7q22, which harbours MUC3A, MUC3B, MUC11 and MUC12 [36, [39] [40] [41] [42] . Further analysis has demonstrated an association of IBD with the intestinal membrane-bound mucin gene MUC3A (Table 1) [41, 42] . It was only recently shown that the gene originally designated MUC3 in fact consists of two genes, MUC3A and MUC3B [40, 41, [43] [44] [45] [46] [47] . The entire structures of both MUC3A and MUC3B, in particular their N-termini, are still unknown, because cloning of sequences containing long stretches of tandem repeats remains difficult. However, both genes encode membrane-bound mucins with two EGF-like motifs, a membrane-spanning domain and a cytoplasmic domain at their C-terminal ends [16, 41] .
The possession of one or two rare alleles of the MUC3A gene, which have an unusual number of 51 base pair repeat units, was associated with ulcerative colitis [42] . It could well be that these unusual forms of MUC3A negatively affect the barrier function within the intestine, conferring a genetic predisposition to ulcerative colitis. Furthermore, it was recently reported that non-synonymous single nucleotide polymorphisms within the cytoplasmic C-terminus of MUC3A, involving a tyrosine residue with a proposed role in epithelial cell signalling, may confer genetic predisposition to Crohn's disease [41] . This indicates that genetic variants of the membrane-bound MUC3A may be involved in predisposition for ulcerative colitis and Crohn's disease by dissimilar mechanisms. Whether other mucin genes on the 7q22 locus are associated with Crohn's disease or ulcerative colitis still remains to be investigated. To date, none of the other mucin genes have genetically been linked to the occurrence of ulcerative colitis or Crohn's disease. In particular, allelic variations of MUC2 were investigated, since MUC2 is the most prominent secretory mucin in the intestines [23] , but no association with ulcerative colitis could be identified [48] .
Changes in human and mouse intestinal mucins are associated with IBD: focus on MUC2
Alterations in mucin synthesis, maturation, secretion, and/or degradation in IBD are generally thought to be involved in the initiation or perpetuation of disease symptoms. The most important alterations in mucin in IBD were recently summarized (Table 1) [49] [50] [51] . These quantitative and/or qualitative alterations in mucin synthesis may be related to mutations within mucin genes, as for MUC3A, or to changes in immunological or microbial factors that influence the mucin expression. The most pertinent data that help us understand the causes and consequences of these alterations come, however, from studies in the mouse, which will be an important focus of this review.
In the mouse, thus far, six Muc-type genes have been identified (Table 2 ) and named after their human orthologues as Muc1, Muc2, Muc3, Muc4 (unpublished, GenBank accession number AF218265), Muc5ac, and Muc5b [52] [53] [54] [55] [56] . Members of the membrane-bound mucins were identified (Muc1, Muc3, and Muc4), as well as of the gel-forming mucins (Muc2, Muc5ac, and Muc5b, which are clustered on mouse chromosome 7), indicating that the mucosal defence and other functions of the mucins are preserved among man and rodent. The mouse is presently the most important model for studying IBD-like pathology. This animal can be genetically and environmentally manipulated enabling us to single out important pathogenic factors in IBD such as the immune system, the enteric bacteria, and the role of mucins in the epithelial barrier.
The colonic mucus layer is thinner in ulcerative colitis [57] , and therefore a deficiency of secretory, gel-form- ing mucins is conceivable. MUC2, as the most prominent secretory mucin in the intestine, seems very important for maintenance of the mucus layer. It was shown that MUC2 synthesis, secretion and sulphation is decreased in active ulcerative colitis [58] [59] [60] , implying diminished mucosal protection in active disease (Table 1) . Most importantly in mice, like humans and rats [23, 61] , Muc2 is the most prominent, heavily sulphated mucin in the intestine, expressed and secreted by all enteric goblet cells [54] . We will present a working model, furnished with recent data, to show that MUC2 may play a critical role in development of IBD.
Bacteria and mucins in IBD
Vast numbers of bacteria roam in the intestines, particularly in the colon, and it is obvious that they pose a serious threat to the intestinal mucosa and development of IBD. Much research effort was put on identifying effects of bacteria in the initiation or perpetuation of IBD. Higher numbers of bacteria have indeed been detected within the colonic mucus layer of IBD patients [62] . These bacteria probably have deteriorating effects on the mucins in the mucus layer. For example, increased levels of faecal mucinase and sulphatase activity, probably of bacterial origin, were found in faecal extracts of patients with IBD, especially in ulcerative colitis [63, 64] . Changes in glycosylation of mucins have been shown to occur in ulcerative colitis [65, 66] , and in vitro faecal anaerobic bacteria have been shown to be able to degrade mucus by producing extracellular glycosidases [67, 68] . Thus, partial degradation of the mucus may increase the exposure of the epithelium to bacteria, bacterial products and other luminal substances, and may constitute a predisposing condition for IBD.
Altered protective efficacy of the intestinal mucus in IBD may result in an increased association of luminal bacteria with the epithelium. Such an increased association may enhance or sustain the inflammatory process during IBD by exposing the mucosal surface to bacterial products and antigens that otherwise would not have been able to pass the mucus barrier. However, it is unknown to what extent luminal enteric bacteria are able to degrade the mucus in vivo. Furthermore, no correlation was found between the number of bacteria in the mucus layer of rectal biopsy specimens and the degree of inflammation [62] . An association between the presence of specific bacterial species and IBD has been suggested but results of numerous studies are inconclusive, as has been recently reviewed [5] . Thus, it seems that the normal commensal enteric bacteria are sufficient to drive the inflammation once it has established itself, and that IBD, as far as we know, is not caused by a specific pathogen.
In humans, it is extremely difficult to establish whether changed bacterial colonization in IBD is either a cause or a consequence of inflammation. Therefore, the presence of bacteria as a pathogenic factor in IBD was studied in germ-free animals, which do not carry any microorganisms, by introduction of normal enteric bacteria (NEB). Germ-free wild-type mice do not develop signs of inflammation after introduction of NEB [3, 69] . Moreover, germ-free mice produce normal amounts of Muc2 compared with mice harbouring NEB, indicating that the presence of bacteria does not lead to an altered mucus thickness per se (Fig. 1A,B) [70, 71] . Introduction of NEB into germ-free mice induced an increase in the sulphation of de-novo synthesized Muc2. Normally colonic mucins are highly sulphated, and sulphated mucins are generally considered to be more resistant to bacterial degradation. A colonic mucus layer composed of less sulphated mucins is deemed less protective, and was closely associated with IBD in humans [23, 60, 64, [72] [73] [74] [75] .
When mice colonized by NEB were treated with luminal dextran sulphate sodium (DSS), a toxic sulphated polysaccharide, colitis develops [76] . DSS initially inhibits proliferation, whereas prolonged DSS treatment results in an induction of hyperproliferation and enhanced apoptosis (Fig. 1C) [77, 78] . Despite the increased turnover of the epithelium and crypt elongation, high expression levels of Muc2 were however maintained, whereas the degree of sulphation of the Muc2 molecules decreased (Fig. 1C) [79, 80] . Introduction of NEB in germ-free mice that are highly susceptible to developing colitis, like interleukin-10 knockout (IL-10 À=À ) mice, rapidly develop severe and chronic colitis on contact with NEB, which is also accompanied by a loss of sulphation of newly synthesized Muc2 molecules (Fig. 1D,E ). This indicates that NEB are only able to elicit colitis in a compromised host (e.g. the IL-10 À=À mice), but not in the healthy mouse. Decreased levels of sulphation of de novo-formed Muc2 is a consistent finding in NEB-associated colitis, which suggests that NEB influence the structure, and possibly the functions, of Muc2 during synthesis. The decreased sulphation in these compromised hosts correlates with the inflammation, and therefore seems a secondary effect of introducing NEB into the colon (Fig. 1A-E ).
Interestingly, a potential therapeutic intervention with probiotic bacteria was recently reported that could increase the MUC2 synthesis in IBD [81] . The probiotic agents Lactobacillus plantarum 299v and Lactobacillus rhamnosus GG quantitatively inhibited the adherence of an entero-pathogenic Escherichia coli to intestinal epithelial cells. These bacteria increased MUC2 and MUC3 mRNA synthesis in these cells, and media containing both these mucins inhibited the binding of Effects of interleukin-10 (IL-10), bacteria, Muc2 and dextran sulphate sodium (DSS) on development of colitis in the mouse. This figure schematically depicts the work of others and our work on diverse inflammatory bowel disease (IBD) models that were developed in mice [3] [4] [5] [69] [70] [71] 79, 80, 82, 87, 93, 94] . The figure summarizes the evidence that both bacteria and damaging agents (like cytotoxic DSS) are particularly detrimental to the colonic mucosa when Muc2 synthesis (the major colonic gel-forming mucin) is low or absent. The models shown are: (1) wild-type mice under germ-free conditions (A) that were infected by normal enteric bacteria (NEB) (B), (2) wild-type mice with NEB, treated with DSS (C), (3) germ-free IL-10 knockout mice (IL-10 À=À ) (D) that were infected with NEB (E), and (4) Muc2 knockout mice (Muc2 À=À ) (F) that were treated with DSS (G). Mice were kept under specified-pathogen-free conditions. The effects of NEB and DSS are depicted as these occur after 1 week of treatment, except for the Muc2 À=À mice treated with DSS (G), which were shown after 2 days of treatment. De-novo Muc2 production was measured under each of these circumstances. The thickness of the extracellular mucus layer signifies the amounts of Muc2 that are produced (gray), while the gray scale indicates the degree of sulphation of Muc2. When Muc2 is depicted in a lighter shade of gray, the degree of sulphation of Muc2 has declined. Changing of Muc2-producing goblet cell morphology in colitis is depicted as the slimming of the goblet cells (gray ellipses). The extent of the inflammation is indicated by the influx of immune cells (black circles). The proliferation is indicated by the occurrence of mitoses in the epithelium ( ) and the apoptosis in the epithelium is indicated by apoptotic cells ( ). Severe ulceration (overt rectal bleeding) occurred in Muc2 À=À mice treated by DSS for 1 day, indicated by the focal absence of epithelium (G). Indicated are further the epithelium (white), the mucosa (stippled), and enteric bacteria (black rectangles).
E. coli to intestinal cells. Thus, it can be hypothesized that these probiotic bacteria increase the epithelial barrier function by inducing synthesis of these important intestinal mucins.
Immunological influence on mucins
A number of rodent models of colitis were recently developed in which chronic intestinal inflammation occurs as a consequence of alterations in the immune system, leading to a failure of normal immuno-regulation in the intestine [2] . These animal models are very suitable for identifying the effects of the immune system on mucin expression. One of these animal models is the IL-10 À=À mouse, which spontaneously develops enterocolitis when maintained in conventional conditions, develops colitis when kept in specified pathogen-free environments, but shows no evidence of colitis when kept germ free ( Fig. 1D ) [69, 82] . In germfree IL-10 À=À mice, at least 10-fold less Muc2 is produced than in germ-free wild-type mice (Fig. 1A,D ) [70, 71] . Although the mucus layer is most probably much thinner as a consequence of the decreased Muc2 synthesis, colitis does not occur because of the absence of a bacterial-derived trigger from the lumen.
On introduction of NEB, the IL-10 À=À mice rapidly develop symptoms of colitis by showing infiltration of immune cells and induction of pro-inflammatory mediators such as IL-12 [70] . The mucosa is thickened and the turnover of epithelial cells is much higher because of increased proliferation in the crypts and apoptosis in the epithelium. Goblet cells become smaller and less apparent (Fig. 1C,E) , which is often referred to as goblet cell depletion. Goblet cell depletion is considered a characteristic feature in IBD and in many of the experimental animal models [1, [83] [84] [85] . However, it is our speculation that the apparent goblet cell depletion might (at least partly) be due to goblet cells losing their characteristic goblet-like shape, rather than a true loss of goblet cells. Thus, the immune imbalance present in the IL-10 À=À mice leads to a primary downregulation of the Muc2 synthesis that is not related to inflammation. The diminished Muc2 levels leave the epithelium barely protected against the influences of NEB. Interestingly, the decreased sulphation in the germ-free IL-10 À=À mice exists without any signs of inflammation, and is also a primary effect of this immune imbalance, instead of the secondary decrease in sulphation that is induced by NEB.
The mechanism by which Muc2 synthesis is downregulated in IL-10 À=À mice remains obscure, yet the finding demonstrates that certain immune regulators directly or indirectly influence mucin production. Participation of cytokines in the regulation of mucin gene expression was implicated in ulcerative colitis through analogy to results obtained with human colorectal cell lines. Exposure of human colonic goblet cell-like cells, LS180, to the pro-inflammatory cytokines IL-1 or IL-6, or tumour necrosis factor-AE resulted in an increased synthesis of MUC2 and other secretory mucins, while addition of each cytokine also resulted in reduced and altered glycosylation [13] . Whereas IL-10 has thus far not been tested directly on cell lines, it seems probable that immune regulators are able to direct mucin expression levels as well as mucin structure.
Muc2 knockout mice are very susceptible to IBD
To directly address the question whether MUC2 is involved in epithelial protection, Muc2-deficient (Muc2 À=À ) mice were generated, through genetic inactivation of the murine Muc2 gene, in the laboratory of Anna Velcich and Leonard Augenlicht (Einstein College, New York) [86] . In Muc2 À=À mice, the intestinal goblet cells are seemingly absent. However, expression of trefoil factor 3, another intestinal goblet cell marker, was still present in a high number of epithelial cells in the colon of the Muc2 À=À mice. Apparently, goblet cells in the absence of Muc2 lose their characteristic goblet-like shape in histology, indicating that Muc2 is the major phenotypic determinant of goblet cells. Muc2 À=À mice spontaneously develop a mild colitis when colonized by NEB under specified-pathogen-free conditions (Fig. 1F ) [87] . However, the Muc2 À=À mice are extremely susceptible to cytotoxic luminal agents like DSS. Treatment with DSS led to very fulminant colitis within days, which was much more severe in each aspect than in wild-type mice treated with DSS ( Fig. 1G ) [87] , indicating that Muc2 plays an essential role in epithelial protection. These findings lend further credibility to the theory that the (partial) deficiency of Muc2 in IL-10 À=À mice predisposes for the development of inflammation. Thus, (partial) deficiency of Muc2 might be an aetiological factor in the onset and/or perpetuation of IBD.
Conclusions
As evidence is fragmentary, we still await the formidable task to elucidate the involvement of mucin in the pathogenesis of IBD. Yet, so far there are two highlights in this field. The state of the art shows that the two most abundant intestinal mucins, the membranebound MUC3 and the secretory MUC2, are clearly implicated in the pathogenesis of IBD. So far, MUC3 is the only human mucin of which particular alleles could be linked to IBD. This linkage of IBD to a genetic predisposition could not be established for MUC2. However, there are now compelling data to suggest that lowered abundance of MUC2 in humans and in experimental animals increases the sensitivity towards IBD. Although it may be still early days for full appreciation of mucins as predisposing factors in IBD, these results are highly encouraging. 
